Redhill Biopharma Ltd. (RDHL) Social Stream
REDHILL BIOPHARMA LTD (RDHL) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering REDHILL BIOPHARMA LTD.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 13 months, RDHL's average price target has gone up $88.19.
Over the past 170 days, RDHL's average upside potential has been 5,884.68%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
RDHL Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 153 days, RDHL's average broker recommendation rating improved by 0.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for RDHL as an investment opportunity.
- RDHL has a lower variance in analysts' estimates than -1389.73% of all US stocks.
- In the context of all US stocks, REDHILL BIOPHARMA LTD's upside potential (average analyst target price relative to current price) is greater than 1640.41% of them.
- In terms of how REDHILL BIOPHARMA LTD fares relative to stocks in the small market cap category, note that its number of analysts covering the stock is higher than 903.79% of that group.
- To contextualize these metrics, consider that out of Healthcare stocks, REDHILL BIOPHARMA LTD's average analyst price target is greater than 592.81% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to REDHILL BIOPHARMA LTD are KMDA, IMMP, and PRQR.
View All Top Stocks by Price Target
Is RDHL a Buy, Hold or Sell? See the POWR Ratings now!